Are financial experts on Wall Street forecasting an increase or a decline in CVS Health's stock value?

CVS Health Corporation: Performance and Analyst Outlook

CVS Health Corporation (CVS), with a market capitalization of $105.4 billion, operates across three main divisions: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness. The company offers a broad spectrum of services, including health insurance, pharmacy benefit management, and retail pharmacy solutions, catering to individuals, businesses, government agencies, and healthcare professionals throughout the United States.

Over the past year, the Woonsocket, Rhode Island-based company has delivered returns that far exceed the overall market. CVS shares have climbed 53.8% in the last 52 weeks, significantly outpacing the S&P 500 Index’s 13.9% gain. Year-to-date, CVS stock is up 5.7%, while the S&P 500 has advanced just 1.5%.

Related News from Barchart

Additionally, CVS has outperformed the State Street Health Care Select Sector SPDR ETF (XLV), which posted a 9.6% return over the same period.

On October 29, CVS shares dropped nearly 2% after the company reported a third-quarter 2025 loss of $3.13 per share. This result was primarily due to a $5.7 billion goodwill impairment in its Health Care Delivery segment, leading to a $3.2 billion operating loss compared to a profit in the prior year. The company also lowered its full-year 2025 earnings guidance to a loss between $(0.34) and $(0.24) per share, down from the previous forecast of $3.84 to $3.94, raising concerns among investors.

Looking ahead, analysts project that CVS’s adjusted earnings per share for the fiscal year ending December 2025 will rise by 22.7% year-over-year to $6.65. The company has a strong track record of surpassing earnings expectations, having beaten consensus estimates for the past four quarters.

Among the 24 analysts tracking CVS, the consensus recommendation is a “Strong Buy,” with 19 rating it as such, two assigning a “Moderate Buy,” and three suggesting a “Hold.”

This analyst sentiment is slightly less optimistic than three months ago, when there were 20 “Strong Buy” ratings.

On January 6, Bernstein increased its price target for CVS Health to $91, while maintaining a “Market Perform” rating.

The average price target stands at $94.74, which is about 13% above the current share price. The highest target on Wall Street is $105, implying a potential upside of 25.2%.